Seaport Therapeutics, Inc. (SPTX)
| Market Cap | 861.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -74.88M |
| Shares Out | 50.67M |
| EPS (ttm) | -1.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SPTX
Seaport Therapeutics is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies. Gl... [Read more]
News
Drug developer Seaport Therapeutics targets $912 million valuation in US IPO
Drug developer Seaport Therapeutics said on Monday it was aiming for a valuation of $912 million in its initial public offering in the United States.
Seaport Therapeutics IPO Registration Document (S-1)
Seaport Therapeutics has filed to go public with an IPO on the NASDAQ
Seaport Therapeutics IPO Registration Document (S-1)
Seaport Therapeutics has filed to go public with an IPO on the NASDAQ